Merck wins UK okay for Keytruda in lung cancer after price cut
December 01, 2016 at 19:01 PM EST
LONDON, Dec 2 (Reuters) - Britain's healthcare cost-effectiveness watchdog NICE has recommended use of Merck's immunotherapy drug Keytruda in certain lung cancer patients, after the U.S. drugmaker cut the price further for the state-run health service.